Classification of endometrial carcinoma: more than two types (Q38215703)

31 August 2017

Classification of endometrial carcinoma: more than two types (English)

1 reference

31 August 2017

endometrial carcinoma

1 reference

1

1 reference

31 August 2017

2

1 reference

31 August 2017

3

Britta Weigelt

1 reference

31 August 2017

1 June 2014

1 reference

Lancet Oncology Commission

31 August 2017

1 reference

31 August 2017

15

1 reference

31 August 2017

e268-78

1 reference

31 August 2017

7

1 reference

31 August 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Recent changes in endometrial cancer trends among menopausal-age U.S. women.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Two pathogenetic types of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Emerging therapeutic targets in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Molecular pathology of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Markers for individualised therapy in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Molecular targets and targeted therapeutics in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Integrated genomic characterization of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Use of mutation profiles to refine the classification of endometrial carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Histotype-genotype correlation in 36 high-grade endometrial carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

High-grade endometrial carcinomas - strategies for typing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Type I and II endometrial cancers: have they different risk factors?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Global burden of obesity in 2005 and projections to 2030.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

The dualistic model of endometrial cancer: the challenge of classifying grade 3 endometrioid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Systematic identification of genomic markers of drug sensitivity in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

New pathologic classification of lung cancer: relevance for clinical practice and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

FGFR2 as a molecular target in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Activating HER2 mutations in HER2 gene amplification negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Genome sequencing identifies a basis for everolimus sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Genome remodelling in a basal-like breast cancer metastasis and xenograft

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970591-6

7 January 2021

10.1016/S1470-2045(13)70591-6

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24872110